Brachy Boost

(redirected from Brachytherapy Boost)
The administration of lower dose (10–25 Gy) implantable radiation (e.g, with 192Ir to treat the local field—e.g., breast, prostate, oral cancer) in addition to external beam radiation of 45–70 Gy
References in periodicals archive ?
"[W]e know that use of a brachytherapy boost is associated with improved patient outcomes, including improved cancer-specific and overall survival," Dr.
The guidelines state that radiation can be given with external beam radiation delivered via a 3D-conformal or intensity-modulated radiotherapy (IMRT) technique, with brachytherapy boost for some tumors where the anatomy permits.
Chris Lee, consultant clinical scientist and head of brachytherapy physics at The Clatterbridge Cancer Centre, commented: "This dual modality treatment has proved extremely successful to date as it gives patients the additional, highly targeted brachytherapy boost to help improve the chances of controlling the disease, while at the same time reducing the dose delivered to the normal surrounding tissue."
The brachytherapy boost treatment has recently had its first annual review, and the promising results mean it can now be taken to the second phase, making the process readily available for an increasing number of patients.
Is single fraction 15 gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?
An eight-year experience of HDR brachytherapy boost for localized prostate cancer: Biopsy and PSA outcome.
During the next 5 months, he received external beam radiation to a dose of 5000 rad followed by high-dose-rate brachytherapy boost of 3 endobronchial applications at 710 rad per fraction (Nucletron MicroSelectron Iridium 192, Nucleotron BV, Veenendaal, The Netherlands).
(4) However, a large proportion of the recurrences are local (about half) so there is a rationale for adding a brachytherapy boost. Hishikawa et al.
Is single fraction 15Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?
Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer.
There have been five RCTs examining the benefit of dose escalation in prostate cancer using higher external beam doses,[sup.1]-[sup.5] and two looking at delivering biologically higher doses using a brachytherapy boost.[sup.6,7] A meta-analysis of five of these trials was done by Viani and colleagues.[sup.8] They found that higher doses decrease the risk of biochemical recurrence by about 1.8%/Gy of radiation (or about 18% risk reduction for an extra week of conventionally fractionated radiation).
Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer.